<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675478</url>
  </required_header>
  <id_info>
    <org_study_id>AC220-A-J101</org_study_id>
    <nct_id>NCT02675478</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Quizartinib</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of
      quizartinib for Japanese acute myeloid leukemia (AML) subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects experiencing adverse events</measure>
    <time_frame>first dose to follow-up, approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of quizartinib and its active metabolite</measure>
    <time_frame>Cycle 1: Days 1, 2, 4, 8, 11, 15, 16, 18, 22, 28; Cycle 2 and on: Days 1, 15</time_frame>
    <description>Evaluate the pharmacokinetics of quizartinib and its active metabolite, AC886 by Cmax, Tmax, AUCtau, Cmax,ss, Ctrough, Tmax,ss, AUCtau,ss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FMS-like tyrosine kinase-3 / internal tandem duplication FLT3/ITD allelic ratio</measure>
    <time_frame>Cycle 1: Days 1, 2, 8, 15</time_frame>
    <description>Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIA assessment</measure>
    <time_frame>Cycle 1: Days 1, 2, 8, 15</time_frame>
    <description>Exploratory assessment of quizartinib-related biomarkers such as FLT3-ITD allelic ratio, PIA assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone marrow findings</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute neutrophil count</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>Cycle 1: Days 15, 28; Cycle 2 and on: Day 28</time_frame>
    <description>Exploratory analyses of tumor response to quizartinib based on bone marrow findings, absolute neutrophil count, and platelet count.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Relapsed AML</condition>
  <condition>Refractory AML</condition>
  <arm_group>
    <arm_group_label>AC220</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC220</intervention_name>
    <arm_group_label>AC220</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory AML

          -  AML for which no standard treatment is available

          -  ECOG Performance Status (PS) of 0 to 2

        Exclusion Criteria:

          -  Acute Promyelocytic Leukemia

          -  chronic myelogenous leukemia in blast phase (BCR-ABL fusion gene positive)

          -  History of other malignancies within 3 years prior to enrollment, except curatively
             treated in-situ carcinoma, AML, or MDS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>phase 1</keyword>
  <keyword>oncology</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

